Cel Sci Corporation (CVM): LEAPS development is further ahead than...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	2
Posts	52
Boards Moderated	0
Alias Born	11/02/2018

cvmibelieve

Re: None

Monday, 03/23/2020 4:44:43 PM

Monday, March 23, 2020 4:44:43 PM

LEAPS development is further ahead than most discern.

Pre-clinical: work has already been conducted at the Rush University Medical Center in Chicago.

2014: (Phase 1) CEL-SCI Received an NIH Grant for (Phase 1) proof of concept and "commercial potential" of LEAPS.

2017: (Phase 2) Two years later Cel-Sci received a SBIR grant for (Phase 2) Research to advanced the efforts achieved in the SBIR Phase 1.

2018: (Phase 2 Accelerator Program ) CEL-SCI was selected into the Commercialization Accelerator Program by the NIH. Only a select number of companies are awarded the SBIR (Phase 2) Commercialization Accelerator Program

LEAPS was specifically selected by the NIH for the Commercialization Transition Track, which provides technical assistance to awardee companies to move NIH-funded technologies towards commercialization and market readiness.

2020: (Phase 3) LEAPS is already on a commercialization path towards an IND application. (Phase 3) is here..."real patients" will soon be treated with LEAPS.